Kornimate/medical-research-clean huggingface dataset:
evaluation of functionnal electromyostimulation on leg in advanced chronic heart failure after hospitalisation for acute decompensation

Conditions: Chronic Heart Failure

Summary: the purpose of the study is to test the efficacy of the functionnal electromyostimulation (fes) of lower limbs in advanced chronic heart failure. the hypothesis is that fes treatment could improve functional exercise capacity.

advanced chronic heart failure (achf) is a severe and frequent disease inducing a strong limitation of exercise capacity and a poor quality of life. hospitalisation for cardiac decompensation is frequent and could alter their incapacities because of muscular deconditionning. tradionnal aerobic rehabilitation exercises fighting against this deconditionning are not relevant in these patients because of dyspnea. in litterature, functionnal electrostimulation (fes) has been tested in stable chronic heart failure (nyha i to iii), far from decompensation. several authors showed the same improvements than those obtained with conventionnal rehabilitation on aerobic capacities (peak vo2, 6 minutes walking test) and quality of life. the originality of this study is to test fes soon after acute heart decompensation in achf patients. this type of rehabilitation could represent in the future an alternative to conventionnal rehabilitation until the patients could be able to do aerobic exercise. 60 patients will be randomised between two groups, the firsth receiving fes (treatment group), the second receiving skin electrostimulation in the same place without muscular contraction (sham group). patient and evaluator do not know what type of stimulation they have. these treatments spread over six weeks, five days per seven. they are began in rehabilitation unit then continued at home. the principal criteria of judgement of fes efficacy is peak vo2 after the protocol. secondary criteria are distance to the six minutes walking test, muscular strengh of quadriceps, the muscle mass measured by dual energy x-ray absorptiometry (dexa), inflamatory dosage (tnf alpha, il-1, il-6, crp), rest value of muscle sympathetic nerve activity, score to minnesota questionnaire and fuctionnal independance. the attempted results are an significative improvement of aerobic capacity(peak vo2 and six minutes walking test) and the others secondary criteria in fes group compared with sham group.

Eligibility criteria:
inclusion criteria: * advanced chronic heart failure (nyha iii to iv) * cardiac ejection fraction \< 40 % * peak vo2 \< 16 ml/kg/min, * optimal drug treatment of chf, * hospitalised for acute decompensation but not in intensive care exclusion criteria: * chronic obstructive pulmonary disease with fev \< 50%, * history of stroke with walking disability, dementia.

Keywords: advanced chronic heart failure, physical therapy, exercise
vısual arts group therapy based on watson's human care model in indıvıduals wıth schızophrenıa

Conditions: Schizophrenia; Art Therapy; Social Support

Summary: purpose: this study was conducted to evaluate the effect of visual arts group therapy based on watson's human care model (vagt-whcm) on perceived social support and functional improvement in individuals with schizophrenia. design: this research was carried out as a randomized controlled experimental study with a pre-test-post-test and follow-up design, which is one of the quantitative research methods. method: the study was carried out in yenimahalle community mental health center between december 2022 and january 2023. the sample of the study consisted of 67 individuals diagnosed with schizophrenia, including the intervention (n=34) and control group (n=33), who met the inclusion criteria and were determined by simple randomization method. vagt-whcm was applied to the intervention group, consisting of six sessions, lasting 90 minutes on average, once a week in three groups. the control group participated only in the routine follow-up, treatment and practices in the institution. the intervention and control groups were evaluated with the "multidimensional scale of perceived social support (mspss)" and the "functional recovery scale (frs)" before therapy (pre-test), post-therapy (post-test), and one month later (follow-up). the consort (consolidated standards of reporting trials) flowcart is used in this study. hypothesis: h1-1: visual arts group therapy has an effect on perceived social support by individuals with schizophrenia. h1-2: visual arts group therapy has an effect on the functional recovery levels of individuals with schizophrenia. h1-3: the change in the perceived social support level of individuals with schizophrenia before and after visual arts group therapy is associated with the change in functional recovery.


Eligibility criteria:
inclusion criteria: * volunteering to participate in the study * meeting the diagnostic criteria for schizophrenia according to dsm-5 and being diagnosed with schizophrenia * being 18 years or older * being in remission (reported by the psychiatrist following the patient in the institution) * having medium and high level of insight (reported by the psychiatrist following the patient in the institution) * ability to read, understand and respond to instructions and data forms used exclusion criteria: * having a diagnosis of a psychotic mental disorder in addition to the diagnosis of schizophrenia * using alcohol or psychoactive substances (reported by the doctor/nurse following the patient in the institution) * having a mental illness that makes cooperation impossible, such as mental retardation or dementia * having a serious physical illness such as cancer * being in an acute psychotic process * having visual, auditory, speech (verbal) and upper extremity defects * having participated in an art therapy program before * continuing any individual therapy or group therapy during the study period

Keywords: schizophrenia visual arts therapy nursing model perceived social support functional recovery randomized controlled study
study of an anti-tlr4 mab in rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: this is a phase 2, poc, randomized, placebo-controlled, double blind, international multicentre study to explore the effect of a new antibody to treat patients with rheumatoid arthritis

the study foresees the randomization of at least 81 moderate to severe, acpa positive, ra patients who are inadequate responders to mtx, in two double blind arms (ni-0101:placebo, with a ratio of 2:1). patients will receive ni-0101 or placebo infusions up to a maximum of 6 administrations (every two weeks for 12 weeks). all patients will continue receiving a stable dose of mtx. after 12 weeks, patients will enter the follow up period with monthly visits for a minimum of 12 weeks.

Eligibility criteria:
inclusion criteria: * male and female patients * age \>= 18 years old * bmi: \ 18 * diagnosis of ra according to 2010 acr/eular criteria and with a disease duration of at least 6 months since diagnosis * patient must present with active ra, characterized by at least 6 swollen joints out of 66 assessed and 6 tender joints out of 68 assessed and by the presence of synovitis (measured by ultrasound) in at least one of the 6 swollen joints * c-reactive protein (crp) level \> 0.7 mg/dl or if the crp level is between 0.3 mg/dl and 0.7 mg/dl (included) then patient must also present an esr \> 30mm/hr * patients must have received mtx treatment for at least 3 months and have been on a stable dose of mtx for at least 6 weeks prior to start of screening * acpa-positive ra patients * women must be postmenopausal (\> 12 months without menses) or surgically sterile or using two effective contraception methods for at least 4 weeks prior to the randomization date and agree to continue contraception for the duration of their participation in the study (until the end of follow up period) * sexually active male patients must use a barrier method of contraception during the course of the study (and until the end of the follow up period) * patients must give written informed consent for study participation exclusion criteria: * a documented history of an autoimmune disease other than ra by acr classification, or sjögren syndrome * administration of cytotoxic drugs and immune suppressants (other than mtx) within 3 months prior to screening * previous multiple administrations of any biological dmard or targeted synthetic dmard * known primary immunodeficiency * pregnant or breastfeeding women * suspicion of active or latent tuberculosis * hiv, hcv, hbv infection * infection reported during screening not recovered 72h prior to first dose * history of anaphylactic reactions to any protein therapeutics or excipients * any history of malignancy, excluding cured basal or squamous cell carcinoma of the skin, or cervical in situ carcinoma * clinically significant cardiac disease requiring medication, such as congestive heart failure, unstable angina, myocardial infarction within 6 months prior to randomization * moderate to severe renal insufficiency, clinically relevant liver function test abnormalities or pancytopenia * major psychiatric or neurological disorder
influenza vaccination in patients receiving immune checkpoint inhibitor

Conditions: Influenza; Solid Carcinoma

Summary: the purpose of this study is to elucidate efficacy and safety of influenza vaccine in cancer patients receiving immune checkpoint inhibitor.

* solid cancer patients receiving immune checkpoint inhibitor or cytotoxic chemotherapy will be recruited 1:2 manner in two hospitals. target numbers are 48 and 95, respectively. * all the participants will be vaccinated for influenza during their chemotherapy when they meet inclusion criteria. * all the participants will be asked if they have any contraindication for influenza vaccine by a physician before vaccination. * hemagglutination inhibition ab titre at pre-vaccination and post-vaccination (21-35 days after vaccination) will be examined in all participants to examine seroprotection rates, seroconversion rates, and changes in geometric mean titer. * and they will be monitored for any vaccination-related adverse reaction or immune-related adverse events after 2-4 days(via phone call), and till 6 months after vaccination (when they visit oncology clinics).

Eligibility criteria:
inclusion criteria: * solid cancer patients receiving immune checkpoint inhibitor or cytotoxic chemotherapeutic agent in seoul national university hospital or seoul national university bundang hospital. * patients who was not vaccinated for influenza in 2018-2019 season * ecog performance status 0 or 1 * patients who fulfilling following laboratory criteria total bilirubin ≤ 1.5 x upper normal limit aspartate transaminase, alanine transaminase ≤ 2.5 x upper normal limit alkaline phosphatase ≤ 2.5 x upper normal limit creatinine ≤ upper normal limit * patients who can understand and agreed with the informed consents. exclusion criteria: * patients having contraindication for influenza vaccination (e.g. egg allergy) * patients who receive any immunosuppressant (excluding steroid for anti-emetic effect) * patients with hiv infection * patients with autoimmune disease who are anticipated to have a problem with immunogenicity for vaccine * patients who have transplanted organ and receive immunosuppressants * patients who are suspected to have active infection (e.g. pneumonia) * patients who receive targeted chemotherapeutic agent alone for cancer treatment * patients who could not receive cancer chemotherapy due to hematologic abnormality at the date of the participation

Keywords: influenza vaccine solid carcinoma immune checkpoint efficacy safety
eus vs tj for liver biopsy and portal pressure gradient measurement

Conditions: Portal Hypertension; Chronic Liver Disease; Cirrhosis

Summary: this study will directly compare the endoscopic ultrasound guided approach to obtain adequate liver biopsies and portal pressure gradient measurements to the current standard of care which uses the transjugular approach.

current guidelines recommend that when a hepatic venous pressure gradient and a liver biopsy are needed, the liver biopsy should be done by the transjugular approach during the same session. a major limitation is that liver biopsies obtained by the transjugular approach meet quality criteria proposed by the american association for the study of liver diseases (at least 2-3cm with at least 11 complete portal tracts) in only 40% of cases. recent studies have shown that endoscopic ultrasound-guided liver biopsy (eus-lb) can achieve a high rate of adequate liver biopsies using the same strict criteria described above. in addition, a novel endoscopic-ultrasound adapted manometer allows the safe and accurate measurement of portal pressure gradient (ppg) which correlates well with hepatic venous pressures (hvpg) obtained by the transjugular approach. unfortunately to this day, no randomized controlled trials has compared the eus-lb and ppg vs tj-lb and hvpg directly.

Eligibility criteria:
inclusion criteria: * age above 18 years * undergoing evaluation for chronic liver disease or portal hypertension * planned to undergo a liver biopsy and hvpg by their treating hepatologist for clinical purposes * signed informed consent exclusion criteria: * uncorrectable coagulopathy (inr above 1.5) * uncorrectable thrombocytopenia (platelets under 50,000) * anticoagulation or antiplatelet therapy that cannot be discontinued * surgically altered upper digestive anatomy * biliary obstruction * grade ii ascites or more * intrahepatic portal vein thrombosis * previous liver transplantation * past hypersensitivity reaction to midazolam or ketamine * history of psychotic disorder * pregnancy

Keywords: eus-portal pressure gradient eus-liver biopsies liver biopsy portal pressure gradient hepatic venous pressure gradient transjugular-portal pressure gradient transjugular-liver biopsies
glutamine for the prevention of radiation toxicity in subjects conserving therapy

Conditions: Breast Cancer

Summary: this study is a single-centered, double-blind, two-arm randomized study to determine if oral glutamine will reduce radiation toxicity for the subjects undergoing breast conserving therapy.


Eligibility criteria:
inclusion criteria: * subject have been diagnosed with stage i or ii invasive breast cancer * subject will undergo accelerated partial breast irradiation (apbi) as part of breast conserving therapy (bct) * subject is eligible for apbi based on american society of therapeutic radiation oncology (astro) criteria * subject is 18 years of age or older * subject is female exclusion criteria: * history of uncontrolled, clinically significant lung, heart, endocrine, liver, or renal disease * subject has been diagnosed with any other cancer * subject has a known hypersensitivity reaction to the following: oral glutamine (gln), glutamate, monosodium glutamate (msg) (i.e., chinese restaurant syndrome) * subject has history of collagen vascular disease * subject has been diagnosed with diabetes mellitus i or ii * subject has had any prior breast radiation * subject is pregnant or breastfeeding

Keywords: breast
study for the revlite laser system for facial solar lentigines

Conditions: Facial Solar Lentigines

Summary: the purpose of this study is to evaluate the effects of the revlite laser system for treatment of facial solar lentigines

prospective facial study using the revlite laser to treat pigmentation caused by sun damage.

Eligibility criteria:
inclusion criteria: 1. is a healthy male or female between 18 and 60 years old. 2. is fitzpatrick skin types i-iii 3. is willing to consent to participate in the study. 4. is willing to comply with all requirements of the study including being photographed, following post treatment care and attending all treatment and follow up visits. 5. has clinically determined mild to severe facial mottled pigmentation (solar lentigines) on the face. exclusion criteria: 1. is female and pregnant, has been pregnant within the last 3 months, is currently breast feeding or planning a pregnancy during the study period. 2. is hypersensitive to light exposure or takes photo sensitized medication. 3. has active or localized systemic infections. 4. has a coagulation disorder or is currently using anti-coagulation medication (including but not limited to the heavy use of aspirin {greater than 81 mg per day}). 5. has any condition which, in the investigator's opinion, would make it unsafe for the subject to participate in this research study. 6. is currently enrolled in an investigational drug or device trial, or has received an investigational drug or been treated with an investigational device within 3 months prior to entering this study. 7. has used accutane within 6 months prior to enrollment. 8. has the need to be exposed to artificial tanning devices or excessive sunlight during the trial. 9. has had prior treatment with parenteral gold therapy (gold sodium thiomalate). 10. has a history of keloids. 11. has evidence of compromised wound healing. 12. has a history of basal cell carcinoma, squamous cell carcinoma or melanoma. 13. has a history of immunosuppression/immune deficiency disorders (including hiv infection or aids) or use of immunosuppressive medications or has an autoimmune disorder.
retrospective identification of scintigraphic cardiac amyloidosis (risca)

Conditions: Cardiac Amyloidosis; Transthyretin Amyloidosis

Summary: this study aims to determine the positive predictive value of incidental cardiac uptake on bone scintigraphy for diagnosing transthyretin cardiac amyloidosis, in patients who underwent scintigraphy for reasons other than suspected amyloidosis. the study is an observational, descriptive, multicenter, national study using retrospective data from routine care. patients with incidental cardiac uptake will be recalled for further diagnostic assessment.


Eligibility criteria:
inclusion criteria: * adults (≥ 18 years) * patients who underwent bone scintigraphy with 99mtc-hmdp/dpd/pyp for any indication * incidental cardiac uptake (perugini grade ≥2) confirmed by a nuclear medicine specialist exclusion criteria: * patients under legal protection * patients refusing the reuse of their data after individual information

Keywords: cardiac amyloidosis bone scintigraphy deep learning
feasibility study and preliminary application study on iris octa

Conditions: Conjunctivitis; Glaucoma; Myopia; Diabetic Retinopathy; Retinal Detachment; Retinal Neovascularization, Unspecified; Uveitis

Summary: all participants will underwent imaging using the octa system (zeiss) with the anterior segment optical adaptor lens. the main outcomes are iris blood flow density and vascular density.

1. feasibility study of iris octa technology 2. establishment of iris octa database in normal population and analysis of related factors: (1) different sex; (2) different age; (3) different myopic diopter; (4) 24-hour diurnal changes from morning to night; (5) before and after mydriasis; (6) different blood pressure; (7) different intraocular pressure; (8) different blood glucose; (9) before and after exercise. (10) drinking water, tea, coffee and red wine. 3. analysis of iris octa data related to eye diseases:(1) conjunctivitis; (2) glaucoma; (3) childhood myopia; (4) uveitis; (5) diabetic retinopathy; (6) retinal detachment; (7) fundus neovascularization. 4. influence of commonly used ophthalmic drops on iris octa data. observe the difference of iris octa test data before and after treatment: (1) conjunctivitis treated with levofloxacin antibiotics; (2) glaucoma treated with prostaglandins, adrenalines and receptor blockers; (3) childhood myopia treated with atropine drugs (4) uveitis treated with hormonal drugs. (5) diabetic retinopathy treated with vasodilator. 5. effect on iris octa data before and after ophthalmic surgery. (1) cataract, phacoemulsification + intraocular lens implantation; (2) glaucoma, iridectomy; (3) fundus neovascularization, intraocular injection of anti-vegf; (4) diabetic retinopathy, vitreous surgery.

Eligibility criteria:
inclusion criteria: * healthy volunteers and ophthalmological patients who can understand and agree to cooperate this study will be included. exclusion criteria: * patients who can not cooperate with the examination.

Keywords: iris vessel octa
efficacy of laser acupuncture on pruritus in patients with chronic kidney disease undergoing hemodialysis

Conditions: Pruritus; Kidney Failure, Chronic

Summary: uremic pruritus is a clinically significant symptom which imposes heavy impact on the quality of life of patients with chronic kidney disease undergoing hemodialysis. in order to investigate the clinical efficacy and mechanism, the investigators designed a multiple centers, randomized, assessor- and participant-blind, controlled, cross-over clinical trial. this trial will be conducted at taichung branch, feng-yuan branch and the eastern branch of cmuh.

we plan to enroll 200 volunteer patients with uremic pruritus. after the waiting period (as the waiting list group), you will be randomized to laser acupuncture and sham laser acupuncture group. each group will include 100 patients and given intervention according to their hemodialysis frequency, i.e., biw or tiw. the intervention will then be crossed over to the other one after 4 week of wash-our period. outcome measurement includes questionnaires, biochemistry analysis, instrumental analysis and medication score.

Eligibility criteria:
inclusion criteria: * age\>20y/o, esrd patient, pruritus symptoms persist longer than 4 weeks exclusion criteria: * immunosupression agents use, undergo chemotherapy * drug abuser * pregnancy women * patient with psychiological disorder * arrhythemia, pacemaker device use * local skin infection over laser acupuncture site * patient allergy to laser acupuncture treament

Keywords: acupuncture laser uremic pruritus randomized clinical trial
the prebeat trial: digital prehabilitation in the cardiac surgical population

Conditions: Cardiovascular Diseases

Summary: the goal of this randomised controlled trial is to learn if a digital prehabilitation program is feasible in patients awaiting cardiac surgery. the main questions it aims to answer are: 1. is the digital health program usable? 2. is the digital health program acceptable? 3. do patients adhere to the digital health program? researchers will compare a group using the digital prehabilitation program with standard care to see if the program is feasible and explore any differences in health outcomes. participants will * use a digital health mobile phone application to guide you through exercise, nutrition and preparation for surgery. * engage in telehealth consultations. * complete questionnaires * complete exercise testing


Eligibility criteria:
inclusion criteria: * 21 days+ prior to cardiac surgery * able to provide consent, * proficient in english to understand questionnaires, training instructions and outcome assessments. * digitally literate to independently navigate a smart device and novel application. exclusion criteria: * severe or unstable neurological, cardiorespiratory, or musculoskeletal disease or mental illness that might compromise ability to perform exercise, * unstable psychiatric or cognitive disorders,

Keywords: digital health telehealth cabg cardiac surgery heart surgery prehabilitation perioperative